These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29652968)

  • 21. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
    Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
    Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
    Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.
    Li J; Udy AA; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2012 Jan; 39(1):69-72. PubMed ID: 22024354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of total and free voriconazole in human plasma: Application to pharmacokinetic study and therapeutic monitoring.
    Resztak M; Kosicka K; Zalewska P; Krawiec J; Główka FK
    J Pharm Biomed Anal; 2020 Jan; 178():112952. PubMed ID: 31708268
    [No Abstract]   [Full Text] [Related]  

  • 27. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monitoring of vancomycin in pediatrics].
    Delicourt A; Touzin K; Lavoie A; Therrien R; Lebel D
    Med Mal Infect; 2012 Apr; 42(4):167-70. PubMed ID: 22424794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients.
    Kato K; Nagao M; Yamamoto M; Matsumura Y; Takakura S; Fukuda K; Ichiyama S
    J Infect Chemother; 2016 Jan; 22(1):27-31. PubMed ID: 26538245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin: over 50 years later and still a work in progress.
    Rybak MJ; Rotschafer JC; Rodvold KA
    Pharmacotherapy; 2013 Dec; 33(12):1253-5. PubMed ID: 24302197
    [No Abstract]   [Full Text] [Related]  

  • 31. [Optimization of antimicrobial therapy based on therapeutic drug monitoring].
    Morita K
    Yakugaku Zasshi; 2011; 131(10):1407-13. PubMed ID: 21963966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring and use of an adjusted body weight strategy for high-dose voriconazole therapy.
    Richards PG; Dang KM; Kauffman CA; Stalker KL; Sudekum D; Kerr L; Brinker-Bodley M; Cheriyan B; West N; Collins CD; Polega S; Malani AN
    J Antimicrob Chemother; 2017 Apr; 72(4):1178-1183. PubMed ID: 28108679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.
    Dolton MJ; McLachlan AJ
    Curr Opin Infect Dis; 2014 Dec; 27(6):493-500. PubMed ID: 25229352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics.
    Allegaert K; Sherwin CM
    Singapore Med J; 2010 Jan; 51(1):88-9. PubMed ID: 20200782
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioavailability of voriconazole in hospitalised patients.
    Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC
    Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.